Meniawy et al.29 also report that lung cancer patients with a higher PD-L1+ proportion of T cells a week following epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) treatment were more likely to progress (OR 30.3, p < 0.01) and had shorter PFS (1.6 vs. 8.8 months; p < 0.01) and OS. This evidence concerns the gene CD274 and lung cancer.